期刊文献+

加替沙星滴眼液家兔药效学试验及临床观察 被引量:1

Pharmacodynamic and Clinical Study of Gatifloxacin Eye Drops in Rabbit
在线阅读 下载PDF
导出
摘要 目的评价加替沙星滴眼液的药效学与临床疗效。方法以氧氟沙星滴眼液为对照,用35只家兔作眼部刺激性和药效学试验,并观察其对25例细菌混合感染性结膜炎、角膜炎患者的临床疗效,给药方法为5次/d,1~2滴/次,疗程7~14d。结果家兔细菌清除率试验组与对照组分别为89.70%和87.88%;临床观察试验组与对照组临床有效率分别为88.00%和84.00%,细菌清除率分别为87.10%和86.67%,均无显著性差异(P>0.05),未见刺激性反应和其他不良反应。结论加替沙星滴眼液对中重度细菌性感染安全、有效。 Objective To investigate the pharmacodynamics and efficacy of gatifloxacin eye drops(GED). Methods To compare the ofloxacin eye drops (OED) and GED, the stimulation and pharmacopsychosis test with 35 rabbits eye and clinical efficacy treated for 25 patients (conjunctivitis and comeitis) with moderate - to - severe bacterial infections. The doses 0. 1 mL divided every 5 h for 7 - 14 d. Efficacy evaluations included bacterial eradication rates and clinical response. Results The bacterial eradication rates were 89.70% for GED and 87.88% for OED respectively in rabbit eye with moderat- to- severe bacteriat infections. Of 50 treated patients, 25 received GED and 25 received OED. The overall efficacy rates (i. e. cure or markedly improved) were 88.00% for GED and 84.00% for OED. The bacterial eradication rates were 87. 10% for GED and 86.67% for OED ( P 〉 0.05), respectively. Both drug regimens were well tolerated, the stimulation and adverse events were few and mild. Conclusion GED is safe and effective for the treatment of moderate- to- severe bacterial infections.
出处 《中国药业》 CAS 2006年第11期31-32,共2页 China Pharmaceuticals
关键词 加替沙星滴眼液 药效学 临床观察 gatifloxaein eye drops pharmacodynamics clinical study
作者简介 刘莹珍,主管药师,研究方向为制剂药学,(电话)0755-27785697,0755-27788311-3336.
  • 相关文献

参考文献2

二级参考文献26

  • 1Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutant bacteria : measurement and potential use of the mutant selection window [J ]. J Infect Dis, 2002,185 : 561.
  • 2Schmitz FJ, Fluit A, Brisse S, et al. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolone against European Staohylococcus aureus isolates[J]. FEMS Immunol Med Microbiol , 1999,26:281.
  • 3Drlica K, Schmitz FJ. Therapeutic options in an era of decreasing antimicrobial susceptibility[J ]. J Chemother, 2002,14( Suppl 2) : 5.
  • 4Zhao X, Drlica K. Restricting the selection of antibiotic- resistant mutant bacteria: A general strategy derived from fluoroquinolone studies[J ]. Clin Infect Dis, 2001,33 (Suppl 3 ) : S147.
  • 5Allen GP,Kaatz W, Rybak MJ. Activities of mutant prevention concentration- targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J]. Antimicrob Agents Chemother, 2003,47(8) : 2606.
  • 6Zhao X, Xu C,Domagala J, et al. DNA topoisomerase targets of the fluoroquinolone :a strategy for avoiding bacterial resistance [J]. Proc Natl Acad Sci USA, 1997,94 : 13991.
  • 7Dong Y, Xu C, Zhao X, et al. Fluoroquinolone action against mycobacteria: effects of C8 substituents on bacterial growth ,survival and resistance. [J ] Antimicrob Agents Chemother,1998,42: 2978.
  • 8Sindelar G, zhao X, Liew A, et al. Mutant prevention concentration (MPC) as a measure of fluoroquinolone potency against mycobacteria [J ]. Antimicrob Agents Chemother, 2000,44 (12):3337.
  • 9Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquinolone concentration on selection of Mycobacterium bovis BCG and Staphylococcus aureus [J ]. Antimicrob Agents Chemother, 1999,43 : 1756.
  • 10Dong Y, Zhao X, Kreiswerth B, et al. Mutant prevention concentration as a measure of antibiotic potency : studies with clinical isolates of Mycobacterium tuberculosis [ J ]. Antimicrab Agents Chemoother , 2000,44 : 2581.

共引文献6

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部